Efficacy of fluoxetine combined with sacubitril/valsartan in treating CHF with comorbid anxiety and depression
LI Ying
GUO Xiujuan
WANG Linlin
LI Minghui
Abstract：Objective To investigate the efficacy of fluoxetine combined with sacubitril/valsartan in the treat-ment of chronic heart failure(CHF)with comorbid anxiety and depression.Methods A total of 108 patients with CHF with comorbid anxiety and depression treated at Hengshui Second People's Hospital from December 2023 to March 2025 were prospectively selected and randomly divided into two groups,with 54 patients in each group.The control group received conventional foundational intervention plus sacubitril/valsartan,while the observation group received additional fluoxetine on the basis of the control group's treatment regimen.After 12 weeks of treatment,the cardiac function,anxiety and depres-sion levels,sleep status,quality of life,and adverse reactions were compared between the observation group and the con-trol group.Results After treatment,the left ventricular ejection fraction and 6-minute walk test distance in the observation group were higher than those in the control group((39.84±5.23)%vs(36.32±5.03)%,(388.62±44.32)m vs(351.77±42.47)m,respectively),with statistically significant differences(t=3.565,4.411,both P＜0.05).After treatment,the scores of the Self-Rating Anxiety Scale,Self-Rating Depression Scale,Pittsburgh Sleep Quality Index,and Minnesota Living with Heart Failure Questionnaire in the observation group were lower than those in the control group((29.68±2.45)points vs(36.18±3.02)points,(31.78±2.71)points vs(34.88±2.96)points,(3.21±1.01)points vs(5.12±1.12)points,(41.46±8.31)points vs(48.52±9.16)points),with statistically significant differences(t=﹣12.283,﹣5.676,﹣9.307,﹣4.195,all P＜0.05).The incidence of adverse reactions was 12.96%(7/54)in the observation group and 18.52%(10/54)in the control group,with no statistically significant difference(χ2=0.628,P＞0.05).Conclusion The combination of fluoxetine and sacubitril/valsar-tan demonstrated efficacy in improving cardiac function,alleviating anxiety and depression,and enhancing sleep and quality of life in patients with chronic heart failure comorbid with anxiety and depression,without increasing the risk of adverse reactions.
Keywords：fluoxetinesacubitril/valsartanchronic heart failureanxietydepressionefficacy
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：4( 1484-1487 )